Table 6.
Monotherapy or combination | Total (N = 377) | Non-HPD (N = 339) | HPD (N = 38) | P value |
---|---|---|---|---|
Monotherapy | 132 | 115 | 17 | 0.121 |
Dual-immunotherapy | 8 | 6 | 2 | |
Combine with chemotherapy/targeted therapy | 237 | 218 | 19 |
HPD: hyperprogressive disease.
Monotherapy or combination | Total (N = 377) | Non-HPD (N = 339) | HPD (N = 38) | P value |
---|---|---|---|---|
Monotherapy | 132 | 115 | 17 | 0.121 |
Dual-immunotherapy | 8 | 6 | 2 | |
Combine with chemotherapy/targeted therapy | 237 | 218 | 19 |
HPD: hyperprogressive disease.